Oculis to Present at Upcoming May Investor Conferences
Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmic and neuro-ophthalmic diseases, has announced its participation in four major investor conferences in May 2025:
- Bio€quity Europe in Bruges (May 12-14)
- Bank of America Healthcare Conference in Las Vegas (May 13-15)
- H.C. Wainwright BioConnect at Nasdaq in New York (May 20)
- Stifel Virtual Ophthalmology Forum (May 27)
CEO Riad Sherif and CFO Sylvia Cheung will present company updates and participate in fireside chats. One-on-one meetings will be available for interested investors through sponsoring institutions. Webcast links will be posted on the company's website.
Positive
- None.
Negative
- None.
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences:
Bio€quity Europe
May 12-14, 2025; Bruges, Belgium
Company update by Riad Sherif, MD, Chief Executive Officer, on May 14 at 11am CET
Bank of America Healthcare Conference
May 13-15, 2025; Las Vegas, USA
Fireside chat with Sylvia Cheung, Chief Financial Officer, on May 14 at 3pm PT
H.C. Wainwright Annual BioConnect at Nasdaq
May 20, 2025; New York, USA
Company update by Sylvia Cheung, Chief Financial Officer, on May 20 at 9:30am ET
Stifel Virtual Ophthalmology Forum
May 27, 2025; Virtual
Fireside chat with Sylvia Cheung, Chief Financial Officer, on May 27 at 1pm ET
The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com
FAQ
What investor conferences will Oculis (OCS) attend in May 2025?
Who will be presenting at the Oculis (OCS) investor conferences in May 2025?
How can investors arrange meetings with Oculis (OCS) management at the May 2025 conferences?
Where can investors find the webcast links for Oculis (OCS) May 2025 conference presentations?
